Zeta’s Bone Marrow Cocktail – DUAL STAIN.
Zeta’s Bone Marrow Cocktail offers dual staining of CD71 and CD33 in bone marrow biopsies, a valuable diagnostic tool used in hematopathology, allowing simultaneous assessment of erythroid precursors and myeloid lineage cells. This is especially useful in evaluating bone marrow cellularity, lineage distribution, and dysplasia, particularly in disorders like myelodysplastic syndromes (MDS), acute leukemias, and post-chemotherapy recovery.
Zeta Corporation offers a cocktail of monoclonal antibodies for IHC including CD71 and CD33. CD33 is a 67 kDa glycosylated transmembrane protein. Acute myeloid leukemia, acute monocytic leukemia (AML-M5), and all cases of myeloid sarcoma are positive for CD33. The excellent sensitivity and specificity for myelomonocytic lineage makes CD33 a useful diagnostic marker for myeloid sarcoma. Analysis of CD33 expression in paraffin-embedded bone marrow biopsy specimens provides another alternative when evaluating acute leukemias. CD71 antibody recognizes a ~90-95 kDa protein identified as cell surface transferrin receptor (CD71). This antibody is highly specific to CD71 and shows no cross-reaction with other related proteins. Transferrin receptor is the serum iron transport protein transferrin. This receptor has been observed to be expressed by normal erythroid and erythroid leukemias. The combination of anti-CD33 (brown) and anti-CD71 (red) is useful to identify most blasts (myeloid and erythroid blasts) in bone marrow.
Specifically for the differentiation of myeloid versus erythroid lineages, Zeta’s Bone Marrow Cocktail helps separate two key hematopoietic compartments in one section. This is especially useful when assessing trilineage hematopoiesis or looking for lineage-specific dysplasia as CD71⁺ cells are typically cytoplasmic and concentrated in erythroid islands and CD33⁺ cells help highlight myeloid precursors scattered or in clusters.
In assessing dysplasia in MDS, identifying abnormal distribution, asynchrony, or lack of expected maturation in erythroid or myeloid lineages can support diagnosis of MDS and helps detect relative lineage expansion or deficiency (e.g., erythroid hypoplasia, myeloid predominance).
In monitoring post-therapy marrow recovery (for post-chemotherapy or post-transplant patients), Zeta’s Bone Marrow Cocktail can help track lineage-specific regeneration, detect residual disease, and distinguish reactive hyperplasia from early relapse.
Zeta’s DUAL STAIN products provide more information from limited tissues, by seeing two related markers on the same slide while also allowing pathologists to see cellular localization and interaction within the tumor environment. Zeta uses one mouse and one rabbit recombinant monoclonal in each cocktail to allow for differential color results.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.